*Current or Former Members of Prasad Lab in Bold
2025
545. Haslam A, Olivier T, Prasad V. How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis. International Journal of Cancer. 2025.
544. Kim MS, Prasad V. Trials that treat what should be observed: SWOG 2308, a study of Mosunetuzumab-axgb in asymptomatic low tumor burden follicular lymphoma. Journal of Cancer Policy. 2025.
543. Høeg TB, Knudsen B, Prasad V. Lessons from COVID-19 patient visitation restrictions: Six considerations to help develop ethical patient visitor policies. Monash Bioethics Review. 2025.
542. Kim MS, Prasad V. FDA approved based on novel surrogate endpoints: Lessons from the voluntary withdrawal of Voxelotor in Sickle Cell Disease. American Journal of Hematology. 2025.
541. Dasaro C., Mandrola J, Murthy, V, Prasad V. The history of angina and its remedies: COURAGE, ORBITA, and a path forward. Cardiology in Review. 2025.
540. Ward W, Prasad V. To reverse rising heart failure mortality, we must address evidence gaps. Circulation: Cardiovascular Quality and Outcomes. 2025.
539. Dasaro C, Prasad V. Concerns regarding the utility of high-risk pancreatic cancer surveillance. JAMA Onc. 2025.
538. Prasad V, Haslam A. Reply to: The value of offering oncofertility counseling in young patients with newly diagnosed cancer Is unquestionable. JAMA Onc. 2025.
2024
537. Prasad V, Haslam A. Long COVID clinics and services offered by top US hospitals: an empirical analysis of clinical options as of May 2023. BMC Health Services Research. 2024.
536. Hall RH, Wright CL, Hughes, GK, Pena AM, Ladd C, Gardner B, McIntire R, Ferrell M, Rubenstein J, Tuia J, Haslam A, Prasad V, Vassar M . Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications. Clinical Therapeutics. 2024
535. Haslam A, Prasad V. A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019. Open Forum Infectious Diseases. 2024.
534. Nee, A, Haslam A, Prasad V. Spending on anticancer drugs among Medicare beneficiaries: Analyzing predictors of drug expenditures. Journal of Cancer Policy. 2024.
533. Prasad V. When Public Health and Government Officials Violate their Own Precautions: Lessons for the Next Crisis. American Journal of Medicine. 2024.
532. Stratton O, Haslam, A, Prasad, V. Analysis of 810 tweets from 25 unofficial ASCO representatives (Featured Voices) at ASCO 2024. Journal of Cancer Policy. 2024.
531. Prasad V, Haslam A, Olivier, T. Are blood-based cancer screening tests ready for primetime? The American Journal of Medicine. 2024.
530. Widera E, Lee TC, Prasad V. Paxlovid awareness, reporting bias. Health Affairs. 2024.
529. Carr NJ, Haslam A., Prasad V. Financial conflicts among physician speakers at the April 12, 2024 Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma? Journal of Cancer Policy. 2024
528. Kim MS, Haslam A, Prasad V. Trend of sales revenue by year for top selling cancer drugs in the US and the effect of loss of market exclusivity. Journal of Cancer Policy. 2024.
527. Mohyuddin GR, Almasri J, Goodman A, Haslam A, Prasad V. The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma. The Oncologist. 2024
526. Kacew AJ, Haslam A, Prasad V, Cifu AS. Cross-sectional evaluation of medical reversals among National Institute of Health guideline practices implemented during the COVID-19 pandemic: how often did experts err in a time of crisis? BMJ Open. 2024.
525. Lipfert C, Kim MS, Haslam A, Prasad V. Recall of ibrutinib and issues with therapeutic approval. BMJ Oncology. 2024.
524. Olivier T, Haslam A, Ochoa D, Fernandez E, Prasad V. Bedside implications of the use of surrogate endpoints in solid and hematological cancers: Implications for our reliance on PFS, DFS, ORR, MRD and more. BMJ Oncology. 2024.
523. Ranganathan S, Benjamin DJ, Haslam A, Prasad V. Social media engagement of supportive care publications in oncology. Journal of Cancer Policy. 2024
522. Olivier T, Haslam A, Prasad V. Postrecurrence treatment in neoadjuvant or adjuvant FDA registration trials: A systematic review. JAMA Oncology. 2024.
521. Olivier T, Haslam A, Burke P, Boutron I, Naudet F, Ioannidis JPA, Prasad V. A novel framework to assess haematology and oncology registration trials: The THEOREMM project. European Journal of Clinical Investigation. 2024.
520. Eden CO, Haslam A, Prasad V. Cancer therapy, gonadal function, and fertility preservation: Narrative review. JCO Oncology Practice. 2024.
519. Haslam A, Ranganathan S, Prasad V, Olivier T. CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. European Journal of Cancer. 2024.
518. Jenei K, Gentilini A, Haslam A, Prasad V. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: A retrospective, comparative analysis. Lancet Oncology. 2024.
517. Haslam A, Prasad V. Publication of observational studies making claims of causation over time. Contemporary Clinical Trials Communications. 2024.
516. Barosa M, Ioannidis JPA, Prasad V. Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies. European Journal of Clinical Investigation. 2024.
515. Haslam A, Kim MS, Elbaz J, Prasad V. The landscape of checkpoint inhibitors in oncology. European Journal of Cancer. 2024.
514. Haslam A, Prasad V. A systematic review of nirmatrelvir/ritonavir and molnupiravir for the treatment of coronavirus disease 2019. Open Forum Infectious Disease. 2024
513. Srinivasan N, Olivier T, Haslam A, Prasad V. Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial. American Journal of Hematology. 2024.
512. Benjamin DJ, Prasad V. Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer. European Journal of Cancer. 2024.
511. Mainou M, Tsapa K, Michailidis T, Malandris K, Karagiannis T, Avgerinos I, Liakos A, Papaioannou M, Terpos E, Prasad V, Tsapas A. Outcomes in randomized controlled trials of therapeutic interventions for multiple myeloma: A systematic review. Critical Reviews in Oncology / Hematology. 2024.
510. Chandra A, Høeg TB, Ladhani S, Prasad V, Duriseti R. School mask mandates and COVID-19: The challenge of using difference-in-differences analysis of observational data to estimate the effectiveness of a public health intervention. Annals of Internal Medicine. 2024.
509. Barosa M, Prasad V. Characteristics of vaccine safety observational studies and authors' attitudes: A systematic review. The American Journal of Medicine. 2024.
508. Nee A, Haslam A, Prasad V. Spending on anticancer drugs among Medicare beneficiaries: Analyzing predictors of drug expenditures. Journal of Cancer Policy. 2024.
507. Donia M, Prasad V. Dual checkpoint inhibition in melanoma with ≥ 1% PD-L1—time to reassess the evidence. JAMA Oncology. 2024
506. Prasad V. When public health and government officials violate their own precautions: Lessons for the next crisis. The American Journal of Medicine. 2024.
505. Prasad V. CAR T cells in multiple myeloma: Lessons learned. Nature Reviews Clinical Oncology. 2024.
504. Olivier T, Haslam A, Prasad V. Health-related quality of life in trials with high rates of early censoring: caution advised. European Journal of Cancer. 2024.
503. Khan A, Khan H, Hughes GK, Ladd C, McIntire R, Gardner B, Peña AM, Schoutko A, Tuia J, Minley K, Haslam A, Prasad V, Vassar M. Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials. Cancer Medicine. 2024.
502. Ranganathan S, Prasad V, Olivier T. The fate of sotorasib: A regulatory failure potentially harming patients. Lancet Oncology. 2024.
501. Elbaz J, Haslam A, Prasad V. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023). Cancer Medicine. 2024.
500. Olivier T, Prasad V. Neoadjuvant followed by adjuvant pembrolizumab in melanoma: Time biases in the data analysis of the SWOG S1801 trial. Translational Oncology. 2024.
499. Lam M, Olivier T, Haslam A, Tuia J, Prasad V. Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis. European Journal of Cancer. 2024.
498. Zugman M, Haslam A, Prasad V. INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomas. Journal of Cancer Policy. 2024.
497. Nay J, Haslam A, Prasad V. Justification for unequal allocation ratios in clinical trials: A scoping review. Contemporary Clinical Trials. 2024.
496. Olivier T, Prasad V. Equal censoring but still informative: When the reasons for censoring differ between treatment arms. European Journal of Cancer. 2024.
495. Wu AQ, Benjamin DJ, Prasad V, Olivier T. Evaluating regulatory consistency for international anti-PD-(L)1 clinical trials. European Journal of Cancer. 2024.
494. Barosa M, Jamrozik E, Prasad V. The ethical obligation for research during public health emergencies: Insights from the COVID-19 pandemic. Medicine, Health Care, and Philosophy. 2024.
493. Haslam A, Tuia J, Miller SL, Prasad V. Systematic review and meta-analysis of randomized trials testing interventions to reduce physician burnout. American Journal of Medicine. 2024.
492. Lesan V, Olivier T, Prasad V. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials. European Journal of Cancer. 2024.
491. Benjamin DJ, Haslam A, Prasad V. Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta-analysis of randomized trials. Cancer Medicine. 2024.
490. Dennis B, Bratten C, Hughes GK, Peña AM, McIntire R, Ladd C, Gardner B, Nowlin W, Livingston R, Tuia J, Haslam A, Prasad V, Vassar M. Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials. BMJ Oncology. 2024.
489. Benjamin DJ, Kalebasty AR, Prasad V. The overall survival benefit in EV-302: Is enfortumab vedotin plus pembrolizumab the new frontline standard of care for metastatic urothelial carcinoma? European Urology Oncology. 2024.
488. Crotty P, Kari K, Hughes GK, Ladd C, McIntire R, Gardner B, Peña AM, Ferrell S, Tuia J, Cohn J, Haslam A, Prasad V, & Vassar M. Assessing patient risk, benefit, and outcomes in drug development: A decade of lenvatinib clinical trials: A systematic review. Targeted Oncology. 2024.
487. Prasad V, Haslam A. COVID-19 vaccines: history of the pandemic’s great scientific success and flawed policy implementation. Monash Bioethics Review. 2024.
486. Prasad V. T-cell lymphoma From CAR T-cell therapy-A new safety notice. JAMA. 2024.
485. Haslam A, Hoeg TB, Prasad V. Estimation of eligibility for and response to CAR-T therapy in the United States. Blood Advances. 2024.
484. Miller SL, Haslam A, Prasad V. Financial conflicts of interest among presenters, panelists and moderators at haematology and oncology FDA workshops. European Journal of Clinical Investigation. 2024.
483. Høeg TB, Haslam A, Prasad V. The importance of falsification endpoints in observational studies of vaccination to prevent severe disease: A critique of a harm–benefit analysis of BNT162b2 vaccination of 5- to 11-year-olds. Epidemiology and Infection. 2024.
482. Dasaro C, Haslam A, Prasad V. Cardiovascular drugs approved for heart failure with reduced ejection fraction and/or post-myocardial infarction exert consistent effects in both populations: A meta-analysis and meta-regression of randomized controlled trials. MedRxIV. 2024.
481. Bardosh K, Krug A, Jamrozik E, Lemmens T, Keshavjee S, Prasad V, Makary MA, Baral S, Høeg TB. COVID-19 vaccine boosters for young adults: A risk benefit assessment and ethical analysis of mandate policies at universities. Journal of Medical Ethics. 2024.
480. Høeg TB, Krug A, Baral S, Jamrozik E, Keshavjee S, Lemmens T, Prasad V, Makary MA, Bardosh K. University-age vaccine mandates: reply to Lam and Nichols. Journal of Medical Ethics. 2024.
479. Knudsen B, Høeg TB, Prasad V. Analysis of tweets discussing the risk of Mpox among children and young people in school (May-October 2022): A retrospective observational study. BMJ Paediatrics Open. 2024.
478. Prasad V. T-Cell Lymphoma From CAR T-Cell therapy—A new safety notice. JAMA. 2024.
477. Olivier T, Prasad V. Sotorasib in KRASG12C mutated lung cancer. The Lancet. 2024.
476. Dasaro C, Haslam A, Prasad V. Discrepancies in estimating excess death by political party affiliation during the COVID-19 pandemic. JAMA Internal Medicine. 2024.
2023
475. Haslam A, Høeg TB, Prasad V. Estimation of eligibility for and response to CAR-T therapy in the United States. Blood Advances. 2023.
474. Miljković M, Tuia J, Olivier T, Haslam A, Prasad V. Cancer drug price and novelty in mechanism of action. JAMA Network Open. 2023.
473. Høeg TB, Ladhani S, Prasad V. Reliance on the highest-quality studies of long Covid is appropriate and not evidence of bias. BMJ Evidence-Based Medicine. 2023.
472. Hughes GK, Sajjadi NB, Gardner B, Ramoin JK, Tuia J, Haslam A, Prasad V, Vassar M. Assessing patient burden and benefit: A decade of cabozantinib clinical trials. International Journal of Cancer. 2023.
471. Barosa M, Jamrozik E, Prasad V. The ethical obligation for research during public health emergencies: Insights from the COVID-19 pandemic. Medicine, Health Care, and Philosophy. 2023.
470. Prasad V, Allely D. Concerns that may limit the utility of zuranolone. JAMA. 2023.
469. Ranganathan S, Haslam A, Tuia J, Prasad V. Characteristics and outcomes of new molecular oncology drug approvals, in combination or monotherapy. Journal of Cancer Policy. 2023.
468. Høeg TB, Prasad V. Rapid antigen testing for COVID-19: Decreasing diagnostic reliability, potential detrimental effects and a lack of evidence to support continued public funding of community-based testing. Public Health in Practice. 2023.
467. Prasad V, Brown ER, Haslam A. Face masks to control the source of respiratory infections: A systematic review of the scientific literature before and after COVID-19. MedRxIV. 2023.
466. Prasad V, Brown ER, Haslam A. A systematic review of evidence behind the CDC guidelines for indoor lightning safety. MedRxIV. 2023.
465. Olivier T, Haslam A, Tuia J, Prasad V. Eligibility for human leukocyte antigen-based therapeutics by race and ethnicity. JAMA Network Open. 2023.
464. Haslam A, Tuia J, Miller S, Prasad V. Systematic review and meta-analysis of randomized trials testing interventions to reduce physician burnout. The American Journal of Medicine. 2023.
463. Walia A, Tuia J, Prasad V. Progression-free survival, disease-free survival and other composite endpoints in oncology: Improved reporting is needed. Nature Reviews Clinical Oncology. 2023.
462. Benjamin DJ, Prasad V. Starting and stopping cancer drugs: The need for randomized trials. Journal of Cancer Policy. 2023.
461. Høeg TB, Haslam A, Prasad V. An analysis of studies pertaining to masks in morbidity and mortality weekly report: Characteristics and quality of studies through 2023. American Journal of Medicine. 2023.
460. Brown E, Haslam A, Prasad V. Flu advice in the U.S. news media changed during the COVID-19 pandemic but not the evidence. European Journal of Epidemiology. 2023
459. Benjamin DJ, Vinay Prasad. Reevaluating adjuvant capecitabine for resected biliary tract cancer. The Oncologist. 2023.
458. Høeg TB, Ladhani S, Prasad V. How methodological pitfalls have created widespread misunderstanding about long COVID. BMJ Evidence-Based Medicine. 2023.
457. Høeg TB, González-Dambrauskas S, Prasad V. Does equipoise exist for masking children for COVID-19? Public Health in Practice. 2023.
456. Olivier T, Haslam A, Prasad V. Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer. BMC Medicine. 2023.
455. Olivier T, Prasad V. Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer. Annals of Oncology. 2023.
454. Walia A, Prasad V. Extended anticoagulation for VTE: what evidence justifies it? Frontiers in Pharmacology. 2023.
453. Høeg TB, Duriseti R, Prasad V. Potential “healthy vaccinee bias” in a study of BNT162b2 vaccine against Covid-19. The New England Journal of Medicine. 2023.
452. Prasad V. Extended hematology-oncology fellowships in bone marrow transplantation, leukemia, lymphoma, and myeloma: What proportion of trainees train and remain at these centers? MedRxIV. 2023.
451. Miller S, Prasad V. Changes in masking policies in US healthcare facilities in the first quarter of 2023: Do COVID-19 cases, hospitalizations, or local political preferences predict loosening restrictions? MedRxIV. 2023.
450. Miller S, Tuia J, Prasad V. Interpretation of wide confidence intervals in meta-analytic estimates: Is the “absence of evidence” “evidence of absence”? MedRxIV. 2023.
449. Lam M, Olivier T, Haslam A, Tuia J, Prasad V. Cost of drug wastage from dose modification and discontinuation of oral anticancer drugs. JAMA Oncology. 2023.
448. Høeg TB, Chandra A, Duriseti R, Ladhani S, Prasad V. Mask mandates and COVID-19: A re-analysis of the Boston school mask study. ArXiv. 2023.
447. Elfar A, Tran AV, Case J, Hughes GK, Mclintire R, Gardner B, Ladd C, Peña AM, Wayant C, Tuia J, Haslam A, Prasad V, Vassar M. An assessment of the clinical trial portfolio of selinexor in solid and non-solid malignancies: A preliminary study at the 7th Annual Joint Research Meeting of the Biomedical, Biological, Neuroscience, Physiology, Forensics. OSU Center for Health Sciences Research Profiles. 2023.
446. Young A, Jelinek T, Hughes G, Gardner B, Ladd C, Peña A, Mclntire R, Carabajal R, Tuia J, Haslam A, Prasad V, Vassar M. Assessing risk/benefit profile of lapatinib in clinical trials: 7th Annual Joint Research Meeting of the Biomedical, Biological, Neuroscience, Physiology, Forensics. OSU Center for Health Sciences Research Profiles. 2023.
445. Olivier T, Tsantoulis P, Prasad V. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. European Urology. 2023.
444. Olivier T, Smith C, Haslam A, Addeo A, Prasad V. Quality of life In the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 To 2022. Journal of Cancer Policy. 2023.
443. Mohyuddin GR, Prasad V. Detecting selection bias in observational studies—When interventions work too fast. JAMA Internal Medicine. 2023.
442. Haslam A, Tuia J, Prasad V. Scoping review of published oncology meta-analyses in high-impact oncology journals. JAMA Network Open. 2023.
441. Prasad V, Kim MS, Haslam A. Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: Changes to hazard ratio and frequency of inappropriate use. BMC. 2023.
440. Haslam A, Prasad V. Evidence base for health care strategies to protect vulnerable patients during the COVID-19 pandemic. JAMA Oncology. 2023.
439. Høeg TB, Krug A, Baral S, Jamrozik E, Keshavjee S, Lemmens T, Prasad V, Makary MA, Bardosh K. University-age vaccine mandates: reply to Lam and Nichols. Journal of Medical Ethics. 2023.
438. Knudsen B, Høeg TB, Prasad V. Analysis of tweets discussing the risk of Mpox among children and young people in school (May-Oct 2022): Public health experts on Twitter consistently exaggerated risks and infrequently reported accurate information. MedRxiv. 2023
437. Haslam A, Prasad V. Cross-sectional analysis of open payments for physicians at designated hemophilia centers in the US (2018–2020). Thrombosis Research. 2023.
436. Tuia J, Haslam A, Prasad V. Profile of the oncology physician workforce and the characteristics of attrition. JCO Oncology Practice. 2023.
435. Walia A, Prasad V. Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC. Journal of Cancer Research and Clinical Oncology. 2023.
434. Olivier T, Haslam A, Prasad V. Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020. BMC Cancer. 2023.
433. Olivier T, Prasad V. PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings. Journal of Cancer Research and Clinical Oncology. 2023.
432. Olivier T, Haslam A, Prasad V. The definition of long COVID used in interventional studies. European Journal of Clinical Investigation. 2023.
431. Olivier T, Haslam A, Prasad V. Is financial toxicity captured in quality of life assessments in oncology randomized clinical trials? Journal of Cancer Policy. 2023.
430. Høeg TB, González‐Dambrauskas S, Prasad V. The United States’ decision to mask children as young as two for COVID-19 has been extended into 2023 and beyond: The implications of this policy. Paediatric Respiratory Reviews. 2023.
429. Walia A, Haslam A, Tuia J, Miljković M, Prasad V. Current landscape of disparity-focused research: A bibliometric analysis of 260 research articles. MedRxIV. 2023.
428. Bhatt A, Haslam A, Prasad V. The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: A systematic review. Journal of Cancer Research and Clinical Oncology. 2023.
427. Tran AA, Prasad V. Visualizing the randomized sham-controlled trial in orthopedic research: Proposed steps to conducting a total knee arthroplasty randomized controlled trial. Journal of Comparative Effectiveness Research. 2023
426. Krohnert K, Haslam A, Høeg TB, Prasad V. Statistical and numerical errors made by the US Centers for Disease Control and Prevention during the COVID-19 pandemic. SSRN Electronic Journal. 2023.
425. Ranganathan S, Prasad V. CME: Is it meeting the mark? The American Journal of Medicine. 2023.
424. Walia A, Prasad V. Current CML guidelines overemphasize second-generation TKIs: Revisiting the paradigm. Blood Cancer Journal. 2023.
423. Bardosh K, Krug A, Jamrozik E, Lemmens T, Keshavjee S, Prasad V, Makary M, Baral S, Høeg T. COVID-19 vaccine boosters for young adults: A risk-benefit assessment and ethical analysis of mandate policies at universities. Journal of Medical Ethics. 2023.
422. Banerjee T, Kim MS, Haslam A, Prasad V. Clinical trials portfolio and regulatory history of idelalisib in indolent non-Hodgkin lymphoma: A systematic review and meta-analysis. JAMA Internal Medicine. 2023.
421. Høeg TB, Prasad V. An evidence double standard for pharmacological versus non-pharmacological interventions: Lessons from the COVID-19 pandemic. Contemporary Clinical Trials Communications. 2023.
420. Haslam A, Olivier T, Prasad V. Design, power, and alpha levels in randomized phase II oncology trials. ESMO Open. 2023.
419. Kim MS, Prasad V. Front‐line chronic lymphocytic leukemia: The role of chemoimmunotherapy. American Journal of Hematology. 2023.
418. Olivier T, Haslam A, Prasad V. Omission of critical Information from clinical trial reports—What to do about uninterpretable results. JAMA Oncology. 2023.
417. Olivier T, Haslam A, Prasad V. Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival? Translational Oncology. 2023.
416. Prasad V, Brown EJ, Haslam A. An empirical analysis of lay media coverage on influenza prevention pre- and post-COVID-19: Mask recommendations were previously rare, now ubiquitous. MedRxIV. 2023.
415. Powell K, Prasad V. Interpreting the results from the first randomised controlled trial of colonoscopy: Does it save lives? BMJ Evidence-Based Medicine. 2023.
414. Buck E, Haslam A, Tuia J, Prasad V. Frequency and characteristics of trials using medical writer support in high-impact oncology journals. JAMA Network Open. 2023.
413. Walia A, Prasad V. Is it time to reconsider molecular response milestones in chronic myeloid leukemia? American Journal of Hematology. 2023.
412. Haslam A, Prasad V. The response rate by tumour type for tissue-agnostic approved drugs. European Journal of Cancer. 2023.
411. Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman A, Booth C, Prasad V, Mohyuddin GR. Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology. Journal of Cancer Policy. 2023.
410. Varatharajan A, Olivier T, Prasad V. Prostate-specific membrane antigen Positron Emission Tomography in the staging of newly diagnosed prostate cancer: Is more sensitivity always better? European Urology. 2023.
409. Haslam A, Olivier T, Tuia J, Prasad V. A systematic review of basket and umbrella trials in oncology: The importance of tissue of origin and molecular target. European Journal of Cancer. 2023.
408. Haslam A, Prasad V. Comparability of control and comparison groups in studies assessing Long COVID. The American Journal of Medicine. 2023.
407. Knudsen B, Prasad V. COVID‐19 vaccine induced myocarditis in young males: A systematic review. European Journal of Clinical Investigation. 2023.
406. Powell K, McCall K, Hooda K, Prasad V, Kakkilaya A. Financial conflicts of interest of physicians followed by neurosurgical journals on Twitter. International Journal of Health Planning and Management. 2023.
405. Haslam A, Olivier T, Tuia J, Prasad V. Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers. BMC Cancer. 2023.
404. Khaki AR, Lythgoe MP, Prasad V. Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint? Journal of Cancer Policy. 2023.
403. Miljković M, Prasad V. PAXLOVID™: A regulatory gamble. The American Journal of Medicine. 2023.
402. Haslam A, Olivier T, Powell K, Tuia J, Prasad V. Eventual success rate and predictors of success for oncology drugs tested in phase I trials. International Journal of Cancer. 2023.
2022
401. Bardosh K, Krug A, Jamrozik E, Lemmens T, Keshavjee S, Prasad V, Makary M, Baral S, Høeg T. COVID-19 vaccine boosters for young adults: A risk-benefit assessment and ethical analysis of mandate policies at universities. Journal of Medical Ethics. 2022.
400. Tran A, Prasad V. Visualizing the randomized sham-controlled trial in orthopedic research: Proposed steps to conducting a total knee arthroplasty randomized controlled trial. Journal of Comparative Effectiveness Research. 2022.
399. Knudsen B, Prasad V. COVID-19 vaccine induced myocarditis in young males: A systematic review. European Journal of Clinical Investigation. 2022.
398. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah A-O, Chakraborty R, Prasad V, Mohyuddin GR. Characteristics of measurable residual disease assessment in myeloma: A review of clinical trials from 2015-2020. Blood Cancer Journal. 2022.
397. Powell K, Kakkilaya A, Haslam A, Prasad V. Financial conflicts of interest of OncoAlert: An informal oncology professional network. Journal of Cancer Policy. 2022.
396. Olivier T, Prasad V. Molecular testing to deliver personalized chemotherapy recommendations: Risking over and undertreatment. BMC Medicine. 2022.
395. Powell K, Prasad V. Common misconceptions of randomized controlled trials in oncology. European Journal of Clinical Investigation. 2022.
394. Bhatt A, Powell K, Prasad V. The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many? Translational Oncology. 2022.
393. Haslam A, Olivier T, Tuia J, Prasad V. A systematic review of basket and umbrella trials in oncology: The importance of tissue of origin and molecular target. European Journal of Cancer. 2022.
392. Miljkovic MD, Tuia JE, Olivier T, Haslam A, Prasad V. Association between US drug price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration from 2015 to 2020. JAMA Internal Medicine. 2022.
391. Kim MS, Prasad V. Pembrolizumab for all. Journal of Cancer Research And Clinical Oncology. 2022.
390. Haslam A, Prasad V. Brentuximab vedotin in advanced hodgkin's lymphoma. The New England Journal of Medicine. 2022.
389. Prasad V, Ioannidis JPA. Constructive and obsessive criticism in science. European Journal of Clinical Investigation. 2022.
388. Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). BMJ Open. 2022.
387. Tuia JE, Olivier T, Prasad VK. Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care. American Journal of Clinical Oncology: Cancer Clinical Trials. 2022.
386. Jenei K, Lythgoe MP, Prasad V. General payments from Biogen to U.S. physicians between 2015 and 2020. Journal of The American Geriatrics Society. 2022.
385. Olivier T, Prasad V. Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later? Translational Oncology. 2022.
384. Iness AN, Abaricia JO, Sawadogo W, Iness CM, Duesberg M, Cyrus J, Prasad V. The effect of hospital visitor policies on patients, their visitors, and health care providers during the COVID-19 pandemic: A systematic review. The American Journal of Medicine. 2022.
383. Prasad V, Olivier T, Chen EY, Haslam A. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross-sectional analysis. Journal of Cancer Policy. 2022.
382. Walia A, Haslam A, Prasad V. FDA validation of surrogate endpoints in oncology: 2005-2022. Journal of Cancer Policy. 2022.
381. Powell K, Burns MC, Prasad V. Relugolix: Five reasons why the US Food and Drug Administration should have exercised restraint. European Urology. 2022.
380. Olivier T, Powell K, Prasad V. Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer: Limitations of the VISION trial. European Urology. 2022.
379. Mohyuddin GR, Mehra N, Ryll B, Prasad V. Control participants of randomised trials: An often forgotten, vulnerable population. The Lancet. Haematology. 2022.
378. Jenei K, Lythgoe MP, Prasad V. CostPlus and implications for generic imatinib. The Lancet Regional Health - Americas. 2022.
377. Olivier T, Haslam A, Prasad V. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. European Journal of Cancer. 2022.
376. Lythgoe MP, Prasad V. Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology. British Journal of Cancer. 2022.
375. Benjamin DJ, Haslam A, Gill J, Prasad V. Targeted therapy in lung cancer: Are we closing the gap in years of life lost? Cancer Medicine. 2022.
374. Haslam A, Prasad V. Characteristics of Facebook's third-party medical fact-checkers. Digital Health. 2022.
373. Benjamin DJ, Prasad V. PI3K inhibitors in haematological malignancies. The Lancet. Oncology. 2022.
372. Powell K, Prasad V. Colorectal cancer screening at a younger age: Pitfalls in the model-based recommendation of the USPSTF. BMJ Evidence-Based Medicine. 2022.
371. Olivier T, Gill J, Prasad V. Corrigendum to 'multi-cancer screening tests: Communicating about risks should be prioritized' AmJMed 2021;135(4):413-415. The American Journal of Medicine. 2022.
370. Powell K, Prasad V. Multiplicity: When many analytic plans are applied or many redundant studies are run, false-positive results are ensured. European Journal of Clinical Investigation. 2022.
369. Van Oekelen O, Birrer N, Wesson W, Galate V, Goodman A, Abdallah A-O, Chakraborty R, Prasad V, Mohyuddin GR. P-053: A systematic review of measurable residual disease (MRD) assessment characteristics in myeloma trials from 2015-2020 Clinical Lymphoma Myeloma And Leukemia. 2022.
368. Etekal T, Koehn K, Sborov D, Mcclune B, Prasad V, Haslam A, Berger K, Booth C, Hadidi SA, Abdallah A-O, Goodman A, Mohyuddin GR. P-135: Time to event surrogate endpoints in multiple myeloma randomized trials from 2005-2019: A systematic review and surrogacy analysis Clinical Lymphoma Myeloma And Leukemia. 2022.
367. Olivier T, Prasad V. Amivantamab and mobocertinib in exon 20 insertions EGFR mutant lung cancer, challenge to the current guidelines. Translational Oncology. 2022.
366. Olivier T, Prasad V. FDA precedents in drug approvals: Contradiction in promoting more treatment options. European Journal of Cancer. 2022.
365. Wright K, Meyers DE, Chisamore TM, McInnes MDF, Sismondo S, Gyawali B, Prasad V, Booth CM. Industry relationships with medical oncologists: Who are the high-payment physicians? JCO Oncology Practice. 2022.
364. Haslam A, Gill J, Prasad V. The frequency of assessment of progression in randomized oncology clinical trials. Cancer Reports. 2022.
363. Goodman AM, Mohyuddin GR, Prasad V. Ivosidenib and azacitidine in IDH1-mutated AML. The New England Journal of Medicine. 2022.
362. Prasad V, Olivier T, Chen EY, Haslam A. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross-sectional analysis. Journal of Cancer Policy. 2022.
361. Olivier T, Prasad V, Marini BL. Hard-wired biases in trials: Maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials. Blood Advances. 2022.
360. Smith CEP, Haslam A, Prasad V. Receipt of subsequent immune checkpoint inhibitors at progression among patients with solid tumors enrolled in clinical trials of adjuvant immune checkpoint inhibitors. Europe PMC. 2022.
359. Yopes MC, Mozeika AM, Liebling S, Haslam A, Prasad V, Lebwohl B. An analysis of 5 Years of randomized trials in gastroenterology and hepatology reveals 52 medical reversals. Digestive Diseases And Sciences. 2022.
358. Kwong F, Lerner K, Tao DL, Patel S, Prasad V. ASCO oral presenters five years later: Leaks in the pipeline? Journal of Clinical Oncology. 2022.
357. Akman EG, Powell K, Haslam A, Prasad V. Characteristics of oncology podcasts: Attitudes, speakers, conflicts. Journal of Cancer Policy. 2022.
356. Mousavi I, Olivier T, Prasad V. Cost per event averted in cancer trials in the adjuvant setting from 2018 to 2022. JAMA Network Open. 2022.
355. Haslam A, Olivier T, Thawani R, Prasad V. Duration of treatment in oncology clinical trials: Does the duration change when the same drug moves from the experimental arm to the control arm? ESMO Open. 2022.
354. Kim MS, Xu A, Haslam A, Prasad V. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020. International Journal of Cancer. 2022.
353. Olivier T, Prasad V. Tebentafusp in first-line melanoma trials: An outperforming outlier. Translational Oncology. 2022.
352. Wayant C, Mohyuddin GR, Prasad V. The accelerated approval pathway in oncology: Balancing the benefits and potential harms. Journal of Cancer Policy. 2022.
351. Kim MS, Prasad V. When we move cancer drugs from the second or third to the first line of treatment: What lessons can we learn from KEYNOTE-177 and JAVELIN-100. BMJ Evidence-Based Medicine. 2022.
350. Olivier T, Prasad V. Frontline dual checkpoint inhibition in metastatic melanoma over anti-PD-1 monotherapy: The case for a comparative randomized controlled trial. Journal of Clinical Oncology: Official Journal of The American Society of Clinical Oncology. 2022.
349. Ahmed N, Vengalasetti Y, Haslam A, Prasad V. Association of adjuvant or metastatic setting with discontinuation of cancer drugs in clinical trials. JAMA Network Open. 2022.
348. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR. Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. European Journal of Cancer. 2022.
347. Powell K, Prasad V. Where are randomized trials necessary: Are smoking and parachutes good counterexamples? European Journal of Clinical Investigation. 2022.
346. Haslam A, Powell K, Prasad V. How often do medical specialties question the practices that they perform? An empirical, cross-sectional analysis of the published literature. Inquiry: The Journal of Health Care Organization, Provision, And Financing. 2022.
345. Herrera-Perez D, Gill J, Haslam A, Crain T, Klossner Q, Prasad V. Frequency of survival to hospital discharge after cardiopulmonary resuscitation on FOX TV's The Resident. European Journal of Emergency Medicine: Official Journal of The European Society For Emergency Medicine. 2022.
344. Olivier T, Gill J, Prasad V. Multi-cancer screening tests: Communicating about risks should be prioritized. The American Journal of Medicine. 2022.
343. Gholami R, Khan R, Ramkissoon A, Alabdulqader A, Gimpaya N, Bansal R, Scaffidi MA, Prasad V, Detsky AS, Baker JP, Grover SC. Recommendation reversals in gastroenterology clinical practice guidelines. Journal of The Canadian Association of Gastroenterology. 2022.
342. Olivier T, Prasad V. The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. Translational Oncology. 2022.
341. Xu A, Prasad V. The use and meaning of the parachute metaphor in biomedicine: A citation analysis of a systematic review and a randomized trial of the parachute for freefall. Journal of Comparative Effectiveness Research. 2022.
340. Jenei K, Prasad V, Lythgoe MP. High US drug prices have global implications. BMJ. 2022.
339. Prasad V, Haslam A, Tuia J. A preliminary study of the rate of hospitals and satellite clinics worldwide for top US cancer centers. Journal of Cancer Policy. 2022.
338. Powell K, Kim MS, Haslam A, Prasad V. Artificial intelligence and magnetic resonance imaging may not make cancer screening better. Journal of Cancer Policy. 2022.
337. Benjamin DJ, Xu A, Lythgoe MP, Prasad V. Cancer drug approvals that displaced existing standard-of-care therapies, 2016-2021. JAMA Network Open. 2022.
336. Maniar A, Haslam A, Prasad V. Evaluating management of progressive disease for control arm patients in trials of first-line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer. 2022.
335. Meirson T, Markel G, Prasad V, Goodman AM, Mohyuddin GR. Post-protocol therapy and informative censoring in the CANDOR study. The Lancet Oncology. 2022.
334. Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin GR. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. British Journal of Haematology. 2022.
333. Lythgoe MP, Prasad V. The last word to new FDA draft guidance for cancer clinical trial eligibility criteria for patients with incurable cancer. Journal of Cancer Policy. 2022.
332. Jenei K, Meyers DE, Prasad V. Use of participation to prevalence ratio for evaluating the representation status of women in oncology clinical trials (In reply). JAMA Oncology. 2022
331. Powell K, Russler-Germain D, Prasad V. Idecabtagene vicleucel: questions regarding the appropriate role and cost. British Journal of Haematology. 2022.
330. Powell K, Haslam A, Prasad V. An empirical analysis of precision previvorship: Are familial and high-risk cancer preventive programs evidence-based? The American Journal of Medicine. 2022.
329. Torgerson T, Wayant C, Cosgrove L, Akl EA, Checketts J, Dal Re R, Gill J, Grover SC, Khan N, Khan R, Marušić A, McCoy MS, Mitchell A, Prasad V, Vassar M. Ten years later: A review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence-Based Medicine. 2022.
328. Haslam A, Kim MS, Prasad V. Overall survival for oncology drugs approved for genomic indications. European Journal of Cancer. 2022.
327. Lythgoe MP, Jenei K, Prasad V. Regulatory decisions diverge over aducanumab for Alzheimer's disease. BMJ. 2022.
326. Kim MS, Cai J, Maniar A, Kartika T, Haslam A, Prasad V. Comparison of classification of Indications for allogeneic and autologous transplant for adults in ASTCT guidelines and evidence available in published literature. JAMA Internal Medicine. 2022.
325. Sharp J, Prasad V. An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first-line advanced non-small cell lung cancer (NSCLC). BMC Cancer. 2022.
324. Meyers DE, Meyers BS, Chisamore TM, Wright K, Gyawali B, Prasad V, Sullivan R, Booth CM. Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. Cancer. 2022.
323. Olivier T, Haslam A, Prasad V. Reporting of physicians' or investigators' choice of treatment in oncology randomized clinical trials. JAMA Network Open. 2022.
322. Powell K, Haslam A, Prasad V. The Kardashian Index: A study of researchers' opinions on Twitter 2014-2021 Scientometrics. 2022.
2021
321. Olivier T, Haslam A, Prasad V. Anticancer drugs approved by the US Food and Drug Administration from 2009 to 2020 according to their mechanism of action. JAMA Network Open. 2021.
320. Jenei K, Raymakers A, Meyers DE, Prasad V. Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020. Journal of Cancer Policy. 2021.
319. Fundytus A, Prasad V, Booth CM. Has the current oncology value paradigm forgotten patients' time? Too little of a good thing. JAMA Oncology. 2021.
318. Lythgoe MP, Krell J, Savage P, Prasad V. Race reporting and diversity in US Food and Drug Administration (FDA) registration trials for prostate cancer; 2006-2020. Prostate Cancer And Prostatic Diseases. 2021.
317. Lythgoe MP, Prasad V. The FDA's latest move to expand eligibility for oncology trials - A double-edged sword? Nature Reviews. Clinical Oncology. 2021.
316. Lythgoe MP, Olivier T, Prasad V. The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. European Journal of Cancer. 2021.
315. Kulkarni PA, Prasad V. Understanding risk of thrombosis with thrombocytopenia syndrome after Ad26.COV2.S vaccination. Frontiers of Medicine. 2021.
314. Olivier T, Prasad V. Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements? Translational Oncology. 2021.
313. Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. Leukemia & Lymphoma. 2021.
312. Gill J, Prasad V. After COVID-19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems. International Journal of Cancer. 2021.
311. Haslam A, Lythgoe MP, Greenstreet Akman E, Prasad V. Characteristics of cost-effectiveness studies for oncology drugs approved in the United States from 2015-2020. JAMA Network Open. 2021.
310. Powell K, Prasad V. Concerning FDA approval of trilaciclib (cosela) in extensive-stage small-cell lung cancer. Translational Oncology. 2021.
309. Lythgoe MP, Prasad V. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implications for oncology and beyond. European Journal of Cancer. 2021.
308. Olivier T, Haslam A, Prasad V. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. Journal of Clinical Epidemiology. 2021.
307. Powell K, Lythgoe MP, Prasad V. The oncologic drugs advisory committee votes of April 2021 - Implications for the fate of accelerated approval. JAMA Oncology. 2021.
306. Olivier T, Prasad V. Sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. Translational Oncology. 2021.
305. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah A-O, Goodman AM, Aziz M, Allen I, Prasad V. Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. European Journal of Cancer. 2021.
304. Desai A, Prasad V. Low-dose computed tomographic screening for lung cancer: Time to implement or unresolved questions? Journal of General Internal Medicine. 2021.
303. Jenei K, Meyers DE, Prasad V. The inclusion of women in global oncology drug trials over the past 20 years. JAMA Oncology. 2021.
302. Kim MS, Prasad V. Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients diverge. European Journal of Cancer. 2021.
301. Kim MS, Prasad V. New drugs and options can enhance patient outcomes: But can they also erode them? European Journal of Cancer. 2021.
300. Gill J, Sarpatwari A, Prasad V. The implications of Industry-funded disease awareness campaigns in the rare disease setting. Mayo Clinic Proceedings. 2021.
299. Sharp J, Khaki AR, Prasad V. Use of second-line Immunotherapy in control arms of randomized clinical trials in kidney cancer: A systematic review. JAMA Network Open. 2021.
298. Haslam A, Gill J, Crain T, Herrera-Perez D, Chen EY, Hilal T, Kim MS, Prasad V. The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009-2018. BMC Cancer. 2021.
297. Prasad V. Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms? European Journal of Clinical Investigation. 2021.
296. Banerjee R, Prasad V. Characteristics of registered studies of chimeric antigen receptor therapies: A systematic review. JAMA Network Open. 2021.
295. Powell K, Prasad V. Old-fashioned Intelligence Will Always Be Needed in Medicine. European Urology Focus. 2021.
294. Haslam A, Kim MS, Prasad V. Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. Annals of Oncology: Official Journal of The European Society For Medical Oncology. 2021.
293. Gill J, Cetnar JP, Prasad V. A timeline of immune checkpoint Inhibitor approvals in small cell lung cancer. Trends In Cancer. 2021.
292. Meyers DE, Chisamore TM, McInnes MDF, Gyawali B, Prasad V, Booth CM. Industry payments to US physicians for cancer therapeutics: An analysis of the 2016-2018 open payments datasets. Journal of Cancer Policy. 2021.
291. Kwon DH, Booth CM, Prasad V. Untangling the PROfound trial for advanced prostate cancer: Is there really a role for olaparib? European Urology. 2021.
290. Meyers DE, Meyers BS, Chisamore TM, Wright K, Gyawali B, Prasad V, Sullivan R, Booth CM. Temporal trends in oncology drug revenue among the world's major pharmaceutical companies: A 2010-2019 cohort study. Journal of Clinical Oncology. 2021.
289. Smith CEP, Prasad V. Assessment of new molecular entities approved for cancer treatment in 2020. JAMA Network Open. 2021.
288. Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, Booth CM. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncology. 2021.
287. Mohyuddin GR, Abdallah A-O, McClune B, Goodman A, Prasad V. Multiple myeloma triplet therapies: Baseline characteristics and control groups. Lancet. 2021.
286. Gill J, Prasad V. N of 1 data sharing: The impact of data sharing within the hematology-oncology drug products division of the US FDA. Trends In Cancer. 2021.
285. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah A-O, Goodman AM, Prasad V. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: A systematic review. Lancet Haematology. 2021.
284. Chen EY, Cook M, Deig C, Arastu A, Prasad V, Nabavizadeh N, Lopez CD, Kardosh A. Application of ASCO value framework to treatment advances in hepatocellular carcinoma. JCO Oncology Practice. 2021.
283. Prasad V, Kim MS. Approval and coverage of cancer drugs in England, Canada, and the US. JAMA Internal Medicine. 2021.
282. Kareff SA, Samtani S, Burotto M, Prasad V, Kim C. Current landscape of immunotherapy trials Involving the programmed cell death protein 1/programmed death-ligand 1 axis in intrathoracic tumors. JTO Clinical And Research Reports. 2021.
281. Gill J, Prasad V. Pembrolizumab for non-muscle-invasive bladder cancer - A costly therapy in search of evidence. JAMA Oncology. 2021.
280 Mohyuddin GR, Koehn K, Abdallah A-O, Goodman AM, Prasad V. Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: A systematic review. JAMA Network Open. 2021.
279. Tao DL, Kartika T, Tran A, Prasad V. Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response? European Journal of Cancer. 2021.
278. Rosen K, Prasad V, Chen EY. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing. European Journal of Cancer. 2021.
277. Desai A, Prasad V. Drug approvals in hepatocellular carcinoma - Filling the nonexistent gap? JAMA Oncology. 2021.
276. DeMartino PC, Miljkovic MD, Prasad V. Potential cost implications for all US Food and Drug Administration oncology drug approvals in 2018. JAMA Internal Medicine. 2021.
275. Haslam A, Gill J, Prasad V. The response rate of alternative treatments for drugs approved on the basis of response rate. International Journal of Cancer. 2021.
274. Goodman AM, Kim MS, Prasad V. Persistent challenges with treating multiple myeloma early. Blood. 2021.
273. Hall WA, Tree AC, Dearnaley D, Parker CC, Prasad V, Roach M, Lawton CAF. Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncology. 2021.
272. Banerjee R, Prasad V. Pragmatic trials with prespecified subgroups: What oncologists can learn from COVID-19. Nature Reviews Clinical Oncology. 2021.
271. Maniar A, Prasad V, Haslam A. A systematic analysis of post-protocol therapy in first-line checkpoint Inhibitor trials. SSRN Electronic Journal. 2021.
2020
270. Gill J, Prasad V. Pembrolizumab for non–muscle-invasive bladder cancer — A costly therapy in search of evidence. JAMA Oncology. 2020.
269. Chen E, Cook M, Deig C, Arastu A, Prasad V, Nabavizadeh N, Lopez C, Kardosh A. Application of ASCO value framework to treatment advances in hepatocellular carcinoma. JCO Oncology Practice. 2020.
268. Hall W, Tree A, Dearnaley D, Parker C, Prasad V, Roach M, Lawton C. Considering benefit and risk before routinely recommending SpaceOAR. Lancet Oncology. 2020.
267. DeMartino P, Miljovic M, Prasad V. Potential cost implications for All US Food and Drug Administration oncology drug approvals in 2018. JAMA Internal Medicine. 2020.
266. Goodman A, Kim MS, Prasad V. Persistent challenges with treating multiple myeloma early. Blood. 2020.
265. Tao D, Kartika T, Tran A, Prasad V. Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response? European Journal of Cancer. 2020.
264. Gill J, Prasad V. N of 1 data sharing: The impact of data sharing within the hematology–oncology drug products division of the US FDA. Trends in Cancer. 2020.
263. Torgerson T, Wayant C, Cosgrove L, Akl E, Checketts J, Dal Re R, Gill J, Grover S, Khan N, Khan R, Marušić A, McCoy M, Mitchell A, Prasad V, Vassar M. Ten years later: A review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence-Based Medicine. 2020.
262. Waters R, Prasad V. How often do highly promising cancer biology discoveries translate into effective treatments? Annals of Oncology. 2020.
261. Banerjee R, Prasad V. Pragmatic trials with prespecified subgroups: What oncologists can learn from COVID-19. Nature Reviews Clinical Oncology. 2020.
260. Rosen K, Prasad V, Chen E. Censored patients in Kaplan–Meier plots of cancer drugs: An empirical analysis of data sharing. European Journal of Cancer. 2020.
259. Desai A, Prasad V. Drug approvals in hepatocellular carcinoma—Filling the nonexistent gap? JAMA Oncology. 2020.
258. Tran A, Prasad V. Drug repurposing for cancer treatments: A well-intentioned but misguided strategy. Lancet Oncology. 2020.
257. Haslam A, Gill J, Prasad V. The response rate of alternative treatments for drugs approved on the basis of response rate. International Journal of Cancer. 2020.
256. Prasad V. Addeo A. The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: Was it a wise decision? No. Annals of Oncology. 2020.
255. Banerjee R, Prasad V. Are observational, real-world studies suitable to make cancer treatment recommendations? JAMA Network Open. 2020.
254. Tran A, Miljkovic M, Prasad V. Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia. Leukemia Research. 2020.
253. Kim MS, Prasad V. US Food and Drug Administration approvals for bruton tyrosine kinase Inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation. Cancer. 2020.
252. Gill J, Cetnar J, Prasad V. A timeline of immune checkpoint inhibitor approvals in small cell lung cancer. Trends In Cancer. 2020.
251. Hilal T, Gonzales-Velez M, Prasad V. Limitations in clinical trials leading to anticancer drug approvals by the US Food and Drug Administration. JAMA Internal Medicine. 2020.
250. Maldonado E, Parsons S, Chen E, Prasad V. Estimation of US patients with cancer who may respond to cytotoxic chemotherapy. Future Oncology. 2020.
249. Tran A, Klossner W, Crain T, Prasad V. Shifting, overlapping and expanding use of “precision oncology” terminology: a retrospective literature analysis. BMJ Open. 2020.
248. Nishikawa G, Booth C, Prasad V. Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice? Cancer. 2020.
247. Perez D, Fox-Lee R, Bien J, Prasad V. Frequency of medical reversal among published randomized controlled trials assessing cardiopulmonary resuscitation (CPR). Mayo Clinic Proceedings. 2020.
246. Chen E, Haslam A, Prasad V. FDA acceptance of surrogate endpoints for cancer drug approval: 1992-2019. JAMA Internal Medicine. 2020.
245. Hey SP, Gerlach CV , Dunlap C, Prasad V, Kesselheim AS. The evidence landscape in precision medicine. Science Translational Medicine. 2020.
244. Tran A, Prasad V. Replacing the NCCN’s blocks with wheels: How should consideration of societal spending be incorporated into oncology practice? PharmacoEconomics. 2020.
243. Hazim A, Mills G, Prasad V, Haslam A, Chen EY. Relationship between response and dose in published, contemporary phase I oncology trials Journal of the National Comprehensive Cancer Network. 2020.
242. Parsons S, Maldonado E, Prasad V. Comparison of drugs used for adjuvant and metastatic therapy of colon, breast, and non-small cell lung cancer. JAMA Network Open. 2020.
241. Gill J, Haslam A, Crain T, Perez D, Prasad V. Comparison of industry payments in 2017 with annual salary in a cohort of academic oncologists (Research letter). JAMA Internal Medicine. 2020.
240. Haslam, A, Prasad, V, Livingston, C. Medical reversals in low‐ and middle‐income countries (Perspectives). International Journal of Health Planning and Management. 2020.
239. Haslam A, Gill J, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Network Open. 2020.
238. Krigel A, Prasad V, Lebwohl B. News coverage of the American Cancer Society’s update to colorectal cancer screening guidelines. Mayo Clinic Proceedings. 2020.
237. Haslam A, Livingston C, Prasad V. Medical reversals in family practice: A review. Current Therapeutic Research. 2020.
236. Haslam A, Herrera-Perez D, Gill J, Prasad V. Patient experience captured by quality-of-life measurement in oncology clinical trials. JAMA Network Open. 2020.
235. Haslam, A., Gill, J., & Prasad, V. An empirical analysis of noninferiority studies in oncology: Are they good enough?, Journal of the National Comprehensive Cancer Network. 2020.
234. Haslam A, Gill J, Prasad V. Oncology Drug Advisory Committee recommendations and the US Food and Drug Administration’s actions. Mayo Clinic Proceedings. 2020.
233. Prasad V. Our best weapons against cancer are not magic bullets. Nature. 2020.
232. Gill J, Prasad V. When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor. Annals of Oncology. 2020.
2019
231. Gay ND, Tao D, Prasad V. Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours. Current Oncology. 2019.
230. Khaki AR, Gadi VK, Prasad V. Clinical risk during the evaluation of genomic risk for hormone-sensitive breast cancer: Ignoring valuable data. Journal of the National Comprehensive Cancer Network. 2019.
229. Prasad V, Booth CM. Multiplicity in oncology randomised controlled trials: A threat to medical evidence? The Lancet Oncology. 2019.
228. Tao D, Prasad V. Concerning survival signal for eltrombopag in MDS/AML. Leukemia & Lymphoma. 2019.
227. de Almeida Carvalho LM, de Oliveira Sapori Avelar S, Haslam A, Gill J, Prasad V. Estimation of percentage of patients With fibroblast growth factor receptor alterations eligible for off-label use of erdafitinib. JAMA Network Open. 2019.
226. Ahn R, Herrera-Perez D, Prasad V. Characteristics of public comments submitted to state health technology assessment programs in Oregon and Washington. JAMA Internal Medicine. 2019.
225. Haslam A, Prasad V, Livingston C. Medical reversals in low‐ and middle‐income countries. The International Journal of Health Planning and Management. 2019.
224. Kim MS, Prasad V. The clinical trials portfolio for on-label and off-label studies of eculizumab. JAMA Internal Medicine. 2019.
223. Beaulieu-Jones BK, Finlayson S, Yuan W, Altman, RB, Kohane IS, Prasad, V, Yu, KH. Examining the use of real-world evidence in the regulatory process. Clinical Pharmacology & Therapeutics. 2019.
222. Aspinall SL, Zhao X, Geraci MC, Good CB, Cunningham FE, Heron BB, Becker D, Lee S, Prasad V. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration. Cancer Medicine. 2019.
221. Luo J, Nishikawa G, Prasad V. A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: An overview of the clinical trials agenda. Journal of Cancer Research and Clinical Oncology. 2019.
220. Gill J, Prasad V. A reality check of the accelerated approval of immune-checkpoint inhibitors. Nature Reviews Clinical Oncology.. 2019.
219. Herrera-Perez D, Haslam A, Crain T, Gill J, Livingston C, Kaestner V, Hayes M, Morgan D, Cifu A, Prasad V. A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. 2019.
218. Chapa J, Haslam A, Prasad V. Interpreting the effectiveness of cancer screening from National Population Statistics: Is it sound practice? Mayo Clinic Proceedings. 2019.
217. Haslam A, Prasad V. Confirmatory trials for drugs approved on a single trial. Circulation: Cardiovascular Quality and Outcomes. 2019.
216. Chen EY, Raghunathan V, Prasad V. An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate endpoint of response rate. JAMA Internal Medicine. 2019.
215. Kim MS, Prasad V. Assessment of accuracy of waterfall plot representations of response rates in cancer treatment published in medical journals. JAMA Network Open. 2019.
214. Nabhan C, Klink A, Prasad V. Real-world evidence — What does it really mean? JAMA Oncology. 2019.
213. Greene P, Prasad V, Cifu A. Should evidence come with an expiration date? Journal of General Internal Medicine. 2019.
212. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open. 2019.
211. Hilal T, Sonbol MB, Prasad V. Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration. JAMA Oncology. 2019.
210. Cifu AS, Vandross AL, Prasad V. Case reports in the age of Twitter. The American Journal of Medicine. 2019.
209. Prasad V.K. Improving the design of pivotal clinical trials. Clinical advances in Hematology & Oncology. 2019.
208. Gill J, Prasad V. Testing healthcare workers for latent tuberculosis: Is it evidence-based, bio-plausible, both or neither? The American Journal of Medicine. 2019.
207. Chen EY, Joshi SK, Tran A, Prasad V. Estimation of study time reduction using surrogate endpoints rather than overall survival in oncology clinical trials. JAMA Internal Medicine. 2019.
206. Gill, J. and V. Prasad, Testing for blinding in sham-controlled studies for procedural interventions: The third-party video method. Canadian Medical Association Journal. 2019.
205. Mandrola J, Cifu A, Prasad V, Foy A. The case for being a medical conservative. The American Journal of Medicine. 2019.
204. Mandrola J, Cifu A, Prasad V, Foy A. The reply. The American Journal of Medicine. 2019.
203. Kim, M.S., G. Nishikawa, and V. Prasad, Cancer screening: A modest proposal for prevention. Cleveland Clinic Journal of Medicine. 2019.
202. Cook RJ, Gill J, Prasad V. Registration studies - When should patients be deemed ineligible for aggressive therapy? Nature Reviews Clinical Oncology. 2019.
201. Haslam A, Crain T, Gill J, Herrera-Perez D, Prasad V. Where does the blame for high health care costs go? An empirical analysis of newspaper and journal articles criticizing health care costs. The American Journal of Medicine. 2019.
200. Haslam A, Hey SP, Gill J, Prasad V. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology. European Journal of Cancer. 2019.
199. Tao D, Schott S, Prasad V. The tradeoff of cancer drug regulatory policy: Faster approvals for one means less knowledge for another. American Journal of Medicine. 2019.
198. Prasad V., Cifu A. The necessity of sham controls. The American Journal of Medicine. 2019.
197. Maldonado E, Parsons S, Chen EY-s, Haslam A, Prasad V. Estimation of U.S. patients with cancer who may respond to cytotoxic chemotherapy. Journal of Clinical Oncology. 2019.
196. Hazim AZ, Chen EY-s, Mills GB, Prasad V. The relationship between response and dose in published, contemporary phase 1 oncology trials. Journal of Clinical Oncology. 2019.
195. Gill J, Prasad V. A method to determine if more than surrogate outcomes were improved: The EMR glitch experiment. Research and Practice in Thrombosis and Haemostasis. 2019.
194. B Gyawali, V Prasad; Making adjuvant therapy decisions with uncertain data. Annuals of Oncology. 2019.
193. Hayes MJ, Prasad V. Association between conflict of interest and published position on tumor-treating fields for the treatment of glioblastoma. Journal of Cancer Policy. 2019.
192. Parikh RB, Prasad V. Reply to C.J. Sweeney et al. Journal of Clinical Oncology. 2019.
2018
191. Parikh RB, Prasad V. Metastasis-free survival in prostate cancer: Faster drug approvals, better drugs? Journal of Clinical Oncology. 2018.
190. Yoo SK, Ahmed AA, Hwang L, Dean M, Ragab OM, Bian SX, Ramey SJ, Prasad V, Thomas CR. Who is tweeting in oncology? Social media (SM) activity among academic leadership in 2018. International Journal of Radiation Oncology, Biology, Physics. 102(3):e430, 2018.
189. Shanbhag S, Prasad V. Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers? European Journal of Cancer. 2018.
188. Awad AA, Yoo SK, Mehta D, Holliday EB, Deville C, Vapiwala N, Wilson LD, Jagsi R, Prasad V, Thomas CR. Meaningful and accurate disclosure of conflict of interest at the ASTRO national meeting: A need for reassessment of current policies, Journal of Oncology Practice. 2018.
187. Nishikawa G, Prasad V. Diagnostic expansion in clinical trials: myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were. BMJ. 2018.
186. Hilal T, Prasad V. Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission. Nature Reviews Clinical Oncology. 2018.
185. Tao D, Prasad V. Choice of control group in randomised cancer medicine trials: are we testing trivialities? Lancet Oncology 2018.
184. Gill J, Prasad V. Improving observational studies in the era of big data. The Lancet. 2018.
183. Hazim A, Prasad V. A pooled analysis of published basket trials in cancer medicine. European Journal of Cancer. 2018.
182. Nishikawa G, Luo J, Prasad V. A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. European Journal of Cancer. 2018.
181. Prasad V., Lindner S. Why is research in early-stage cancer research so low? Journal of Cancer Policy. 2018.
180. Haslam A, Prasad V. Multivitamins do not reduce cardiovascular disease and mortality and should not be taken for this purpose: How do we know that? Circulation: Cardiovascular Quality and Outcomes. 2018.
179. Gill J, Obley AJ, Prasad V. Direct-to-consumer genetic testing the implications of the US FDA’s first marketing authorization for BRCA mutation testing. JAMA. 2018.
178. Nastoupil LJ, Prasad V, Flowers CR. The need to assess financial adverse events. Lancet Haematology. 2018.
177. Deloughery EP, Prasad V. If the IMPROVE-IT trial was positive, as reported, why did the FDA deny expanded approval for ezetimibe and simvastatin? An explanation of the tipping point analysis. Journal of General Internal Medicine. 2018.
176. Chen EY-s, Joshi SK, Prasad V. FDA acceptance of surrogate endpoints in later lines of therapy. Journal of Clinical Oncology. 2018. (view on external site through UCSF eScholarship link)
175. Tao DL, Gay ND, Prasad V. Statistical significance of bevacizumab trials when considering the portfolio of all studies. Journal of Clinical Oncology. 2018. (view on external site through UCSF eScholarship link)
174. Gyawali B, Prasad V. Pemetrexed in nonsquamous non–small-cell lung cancer: The billion-dollar subgroup analysis. JAMA Oncology. 2018.
173. Prasad V. Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: Implications for payers and policy makers. Nature Reviews Clinical Oncology. 2018.
172. Prasad V, McCabe C, Mailankody S. Low-value approval and high prices might incentivize ineffective drug development. Nature Reviews Clinical Oncology. 2018.
171. Marquart J, Chen EY, Prasad V. Estimation of the percentage of us patients with cancer who benefit from genome-driven oncology. JAMA Oncology. 2018.
170. Shatzel, J. J., M. M. Daughety, V. Prasad, and T. G. DeLoughery. PFO closure for secondary stroke prevention: is the discussion closed?, Journal of Thrombosis and Thrombolysis. 2018.
169. Prasad V, Kaestner V, Mailankody S. Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncology. 2018.
168. Haslam A, Prasad V. When is crossover desirable in cancer drug trials and when is it problematic? Annals of Oncology. 2018.
167. Gerrity MS, Prasad V, Obley AJ. Concerns about the approval of nusinersen sodium by the US Food and Drug Administration. JAMA Internal Medicine. 2018.
166. Hernandez I, Prasad V, Gelad WF. Total costs of chimeric antigen receptor t-cell immunotherapy. JAMA Oncology. 2018.
165. DeLoughery EP, Prasad V. The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: Implications for subsequent evidence generation. Annuals of Oncology. 2018.
164. Kaestner V, Edmiston JB, Prasad V. The relation between publication rate and financial conflict of interest among physician authors of high-impact oncology publications: An observational study. CMAJ Open. 2018.
163. Prasad V. Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of foundation medicine (F1CDx) before paying for it. Annals of Oncology. 2018.
162. Shatzel JJ, Daughety MM, Prasad V, DeLoughery TG. Reversal of warfarin era thinking. Journal of Internal Medicine. 2018.
161. Chen EY, Prasad V. Crossover is not associated with faster trial accrual. Annuals of Oncology. 2018.
160. Hayes MJ, Kaestner V, Mailankody S, Prasad V. Most medical practices are not parachutes: A citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ Open. 2018.
159. Prasad V. Nusinersen for Spinal Muscular Atrophy: Are we paying too much for too little? JAMA Pediatrics. 2018.
158. Rosa A, Prasad V. Do limitations in the design of PARADIGM-HF justify the slow real-world uptake of sacubitril/valsartan (entresto)? Cardiovascular Drugs and Therapy. 2018.
157. Wagner J, Marquart J, Ruby J, et al. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: Retrospective observational study. BMJ. 2018.
156. Prasad, V. et al. Rebuttal to paper by Kurzrock. 2018.
155. Luo J, Prasad V. The US Food and Drug Administration’s use of pathologic complete response as regulatory endpoint: Did it pay off? Journal of Cancer Policy. 2018.
154. Prasad V. Cost-effectiveness of nusinersen for spinal muscular atrophy — Reply. JAMA Pediatrics. 2018.
153. Hayes MJ, Prasad V. Financial conflicts of interest at FDA drug advisory committee meetings. Hastings Center Report. 2018.
2017
152. Lu E, Shatzel J, Shin F, Prasad V. What constitutes an “unmet medical need” in oncology? An empirical evaluation of author usage in the biomedical literature. Seminars in Oncology. 2017.
151. Prasad V. Do cancer drugs improve survival or quality of life? BMJ. 2017.
150. Prasad V, Kaestner V, Mailankody S. Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncology. 2018.
149. Tayapongsak Duggan K, De Jesus K, Kemp R, Prasad V. Use of word “unprecedented” in the media coverage of cancer drugs: Do “unprecedented” drugs live up to the hype? Journal of Cancer Policy. 2017.
148. Prasad V. Unanticipated outcomes: A medical memoir — A book review. JAMA Internal Medicine. 2017.
147. Prasad V. Non-inferiority trials in medicine: Practice changing or a self-fulfilling prophecy? Journal of General Internal Medicine. 2017.
146. Tao DL, Boothby A, McLouth J, Prasad V. Financial conflicts of interest among hematologist-oncologists on Twitter. JAMA Internal Medicine. 2017.
145. Kaestner V, Prasad V. The availability of jobs in the biopharmaceutical industry is 45-fold greater for hematology-oncology than medical specialties. Blood Cancer Journal. 2017.
144. Kaestner V, Prasad V. Financial conflicts of interest among editorialists in high-impact journals. Blood Cancer Journal. 2017.
143. Prasad V, Kaestner V. Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Seminars in Oncology. 2017.
142. Kemp R, Prasad V. Surrogate endpoints in oncology: When are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Medicine. 2017.
141. Dreicer JJ, Mailankody S, Fahkrejahani F, Prasad V. Clinically meaningful benefit: real-world use compared against the American and European guidelines. Blood Cancer Journal. 2017.
140. Mailankody S, Prasad V. Pharmaceutical marketing for rare diseases regulating drug company promotion in an era of unprecedented advertisement. JAMA. 2017.
139. Goldstein, D. A., Bilal, U. and Prasad, V. Pembrolizumab as first‐line therapy in programmed death ligand 1–positive advanced lung cancer: Is it as effective as we think it is? Cancer. 2017.
138. Lammers A, Edmiston J, Kaestner V, Prasad V. Financial conflict of interest and academic influence among experts speaking on behalf of the pharmaceutical industry at the US Food and Drug Administration's oncologic drugs advisory committee meetings. Mayo Clinical Proceedings. 2017.
137. Prasad V, De Jesus K, Mailankody S. A further strategy to combat the high price of anticancer drugs. Nature Reviews Clinical Oncology. 2017.
136. Gyawali B, Prasad V. Combining drugs and extending treatment - A PFS endpoint is not sufficient. Nature Reviews Clinical Oncology. 2017.
135. Kaestner V, Brown A, Tao D, Prasad V. Conflicts of interest in Twitter. Lancet Haematology. 2017.
134. Prasad V. How the USPSTF's mammographic screening guidelines should be interpreted. The American Journal of Medicine. 2017.
133. Gyawali B, Prasad V. Drugs that lack single-agent activity: Are they worth pursuing in combination? Nature Reviews Clinical Oncology. 2017.
132. De Jesus-Morales K, Prasad V. Closed financial loops: When they happen in government, they're called corruption; In medicine, they're just a footnote. Hastings Center Report. 2017.
131. Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Internal Medicine. 2017.
130. Gyawali B, Prasad V. Health policy: Me-too drugs with limited benefits - The tale of regorafenib for HCC. Nature Reviews Clinical Oncology. 2017.
129. Prasad V, De Jesus K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nature Reviews Clinical Oncology. 2017.
128. Lammers A, Wang R, Cetnar J, Prasad V. Time from US Food and Drug Administration approval to publication of data for cancer drugs: A comparison of first and subsequent approvals. Blood Cancer Journal. 2017.
127. Prasad V, Wang R, Afifi S, Mailankody S. The rising price of cancer drugs — A new old problem? JAMA Oncology. 2017.
2016
126. Prasad V, Oseran A. Multiple comparisons in variation of care research. University of Ottawa Journal of Medicine. 2017.
125. Mailankody S, Prasad V. Overall survival in cancer drug trials as a new surrogate endpoint for overall survival in the real world. JAMA Oncology. 2017.
124. Lammers A, DeLoughery T, Prasad V. Heparin-induced thrombocytopenia: A tremendous opportunity for randomization. Blood Coagulation and Fibrinolysis. 2017.
123. Vandross A, Prasad V, Mailankody S. ASCO plenary sessions: Impact, legacy, future. Seminars in Oncology. 2016.
122. Vaduganathan M, Prasad V. Cardiovascular risk assessment in oncological clinical trials: Is there a role for centralized events adjudication? European Journal of Heart Failure. 2016.
121. Prasad V, Oseran A, Fakhrejahani F. The use of gene expression profiling and mutation analysis increases the cost of care for patients with carcinoma of unknown primary: Does it also improve survival? European Journal of Cancer. 2016.
120. Prasad V, Mailankody S. The UK cancer drugs fund experiment and the US cancer drug cost problem: Bearing the cost of cancer drugs until It Is unbearable. Mayo Clinical Proceedings. 2016.
119. Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to “save lives” — And what we can do about it. BMJ. 2016.
118. Prasad V, Kumar H, Mailankody S. Ethics of clinical trials in low-resource settings: Lessons from recent trials in cancer medicine. Journal of Global Oncology. 2016.
117. Abola MV, Prasad V. Industry funding of cancer patient advocacy organizations. Mayo Clinical Proceedings. 2016.
116. Prasad V, Gale RP. Precision medicine in acute myeloid leukemia: Hope, hype or both? Leukemia Research. 2016.
115. Prasad V, Fojo T, Brada M. Precision oncology: Origins, optimism, and potential. Lancet Oncology. 2016.
114. Prasad V. Precision medicine in diffuse large B-cell lymphoma: Hype or hope? European Journal of Cancer. 2016.
113. Prasad V. Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials? Medical Hypotheses. 2016.
112. Prasad V. How should research be funded? Difficulties with the argument for proportionality to causes of death or years of life lost. Journal of the National Comprehensive Cancer Network. 2016.
111. Prasad V, Rajkumar SV. Conflict of interest in academic oncology: Moving beyond the blame game and forging a path forward. Blood Cancer Journal. 2016.
110. Prasad V. Translation failure and medical reversal: Two sides to the same coin. European Journal of Cancer. 2016.
109. Parikh RB, Prasad V. Blood-based screening for colon cancer: A disruptive innovation or simply a disruption? JAMA. 2016.
108. Massey PR, Wang R, Prasad V, Bates SE, Fojo T. Assessing the eventual publication of clinical trial abstracts submitted to a large annual oncology meeting. Oncologist. 2016.
107. Prasad V. Perspective: The precision-oncology illusion. Nature. 2016.
106. Mailankody S, Prasad V. Implications of proposed medicare reforms to counteract high cancer drug prices. JAMA. 2016.
105. Mailankody S, Prasad V. Thinking systematically about the off-label use of cancer drugs and combinations for patients who have exhausted proven therapies. Oncologist. 2016.
104. Kim C, Prasad V. Strength of validation for surrogate endpoints used in the US Food and Drug Administration's approval of oncology drugs. Mayo Clinic Proceedings. 2016.
103. Gyawali B, Prasad V. Same data; Different Interpretations. Journal of Clinical Oncology. 2016.
102. Dhruva SS, Prasad V. Application of Medicare’s new technology add-on payment program for blinatumomab. JAMA Oncology. 2016.
101. Cifu A, Prasad V. Wearables, smartphones and novel anticoagulants: We will treat more atrial fibrillation, but will patients be better off? Journal of General Internal Medicine. 2016.
100. Boothby A, Wang R, Cetnar J, Prasad V. Effect of the American Society of Clinical Oncology’s conflict of interest policy on information overload. JAMA Oncology. 2016.
99. Bien J, Prasad V. Future jobs of FDA’s haematology-oncology reviewers. BMJ. 2016.
98. Beer TM, Prasad V. Taking care of our friends and neighbors: DeVita’s the death of cancer and the challenge of letting go. JAMA Oncology. 2016.
97. Abola MV, Prasad V. Characteristics and conflicts of public speakers at meetings of the oncologic drugs advisory committee to the US Food and Drug Administration. JAMA Internal Medicine. 2016.
96. Abola MV, Prasad V. The use of superlatives in cancer research. JAMA Oncology. 2016.
2015
95. Tilak G, Prasad V, Jena AB. Authorship inflation in medical publications. Inquiry: A Journal of Medical Care Organization, Provision and Financing. 2015.
94. Thomas A, Chen Y, Yu T, Gill A, Prasad V. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015.
93. Prasad V, Vandross A. Characteristics of exceptional or super responders to cancer drugs. Mayo Clinical Proceedings. 2015.
92. Prasad V, Oseran A. Do we need randomised trials for rare cancers? European Journal of Cancer. 2015.
91. Prasad V, Mailankody S. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. Blood. 2015.
90. Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: A systematic review of trial-level meta-analyses. JAMA Internal Medicine. 2015.
89. Prasad V, Goldstein JA. Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at clinicaltrials.gov. European Journal of Cancer. 2015.
88. Prasad V, Diener-West M. Primary chemoprevention of breast cancer: Are the adverse effects too burdensome? Canadian Medical Association Journal. 2015.
87. Prasad V, Bilal U. The role of censoring on progression-free survival: Oncologist discretion advised. European Journal of Cancer. 2015.
86. Prasad V, Berger VW. Hard-wired bias: How even double-blind, randomized controlled trials can be skewed from the start. Mayo Clinical Proceedings. 2015.
85. Prasad V. But how many people died? Health outcomes in perspective. Cleveland Clinic Journal of Medicine. 2015.
84. Prasad V. Prostate cancer screening: The pendulum has swung, and the burden of proof Is with proponents. American Family Physician. 2015.
83. Prasad V. Non-invasive, serum DNA pregnancy testing leading to incidental discovery of cancer: A good thing? European Journal of Cancer. 2015.
82. Prasad V. Use of the word “Cure” in the oncology literature. American Journal of Hospice and Palliative Medicine. 2015.
81. Massey PR, Prasad V, Figg WD, Fojo T. Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology & Therapy. 2015.
80. Mailankody S, Prasad V. Susan Bates, M.D., and Antonio “Tito” Fojo, M.D., Ph.D.: Thirty years of research, discovery, service, and mentorship at the National Cancer Institute. The Oncologist. 2015.
79. Mailankody S, Prasad V. Five years of cancer drug approvals: Innovation, efficacy, and costs. JAMA Oncology. 2015.
78. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US Food and Drug Administration approvals. JAMA Internal Medicine. 2015.
77. Jena AB, Prasad V, Goldman DP, Romley J. Mortality and treatment patterns among patients hospitalized with acute cardiovascular conditions during dates of national cardiology meetings. JAMA Internal Medicine. 2015.
76. Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T. Colorectal cancer survival gains and novel treatment regimens: A systematic review and analysis. JAMA Oncology. 2015.
75. Huded C, Prasad V. Meta-analyses of statin therapy for primary prevention do not answer key questions: An empirical appraisal of 5 years of statin meta-analyses. American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions. 2015.
74. Goldstein JA, Prasad V. Disease-specific productivity of American cancer hospitals. PLoS ONE. 2015.
73. Cifu AS, Prasad VK. Medical debates and medical reversal. Journal of General Internal Medicine. 2015.
72. Burotto M, Prasad V, Fojo T. Non-inferiority trials: why oncologists must remain wary. Lancet Oncology. 2015.
71. Burotto M, Prasad V. Emphasizing unique strengths and eliminating redundancy for research in low-income and middle-income countries: Lessons from a South American country. Cancer. 2015.
70. Rho J, Ho N, Prasad V. Roflumilast in COPD: Response. CHEST. 2015.
2014
69. Vaduganathan M, Prasad V. Modern drug development: Which patients should come first? JAMA. 2014.
68. Selvaraj S, Borkar DS, Prasad V. Media coverage of medical journals: Do the best articles make the news? PLoS One. 2014.
67. Rho J, Ho N, Prasad V. Counterpoint: were industry-sponsored roflumilast trials appropriate? No. Chest. 2014.
66. Prasad V, Vandross A. Failing to improve overall survival because post-protocol survival is long: Fact, myth, excuse or improper study design? Journal of Cancer Research and Clinical Oncology. 2014.
65. Prasad V, Rho J, Selvaraj S, Cheung M, Vandross A, Ho N. Can a resident's publication record predict fellowship publications? PLoS One. 2014.
64. Prasad V, Massey PR, Fojo T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. Journal of Clinical Oncology. 2014.
63. Prasad V, Mailankody S. The accelerated approval of oncologic drugs: Lessons from ponatinib. JAMA. 2014.
62. Prasad V, Jena AB. The Peltzman effect and compensatory markers in medicine. Healthcare (Amsterdam, Netherlands). 2014.
61. Prasad V, Ioannidis JP. Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices. Implementation Science. 2014.
60. Prasad V, Ho N. Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials? Journal of Clinical Epidemiology. 2014.
59. Prasad V, Grady C. The misguided ethics of crossover trials. Contemporary Clinical Trials. 2014.
58. Prasad V, Goldstein JA. US News and World Report Cancer hospital rankings: Do they reflect measures of research productivity? PLoS ONE. 2014.
57. Prasad V, Cifu A. Eliminating chronic kidney disease... as a diagnosis. Polskie Archiwum Medycyny Wewnetrznej. 2014.
56. Prasad V. Shameful. Canadian Medical Association Journal. 2014.
55. Prasad V. Rosiglitazone, medical reversal, and back to basics for diabetes. American Family Physician. 2014.
54. Prasad V. Statins, primary prevention, and overall mortality. Annals of Internal Medicine. 2014.
53. Prasad V. The withdrawal of drugs for commercial reasons: The incomplete story of tositumomab. JAMA Internal Medicine. 2014.
52. Prasad V. It is time to stop screening for prostate cancer (Invited commentary). JAMA Internal Medicine. 2014.
51. Prasad V. Balloon brachytherapy for breast cancer prove that it works? Or, prove that it doesn't? Journal of Cancer Research and Clinical Oncology. 2014.
50. Mailankody S, Prasad V. Comparative effectiveness questions in oncology. New England Journal of Medicine. 2014.
49. Jena AB, Sun EC, Prasad V. Does the declining lethality of gunshot injuries mask a rising epidemic of gun violence in the United States? Journal of General Internal Medicine. 2014.
48. Jena AB, Prasad V, Romley JA. Long-term effects of the 2003 ACGME resident duty hour reform on hospital mortality. Mayo Clinic Proceedings. 2014.
47. Jena AB, Prasad V. Primary care physicians' role in counseling about gun safety. American Family Physician. 2014.
46. Jena AB, DePasse JW, Prasad V. The declining demand for hospital care as a rationale for duty hour reform. Journal of General Internal Medicine. 2014.
45. Abola MV, Prasad V, Jena AB: Association between treatment toxicity and outcomes in oncology clinical trials. Annals of Oncology. 2014
2013
44. Shea N, Prasad V. Open Issues with open access publication. The American Journal of Medicine. 2013.
43. Selvaraj S, Prasad V. Characteristics of cluster randomized trials: Are they living up to the randomized trial? JAMA Internal Medicine. 2013.
42. Prasad V, Vandross A, Toomey C, et al. A decade of reversal: An analysis of 146 contradicted medical practices. Mayo Clinic Proceedings. 2013.
41. Prasad V, Rho J, Cifu A. The inferior vena cava filter: How could a medical device be so well accepted without any evidence of efficacy? JAMA Internal Medicine. 2013.
40. Prasad V, Jorgenson J, Ioannidis JP, Cifu A. Observational studies often make clinical practice recommendations: An empirical evaluation of authors' attitudes. Journal of Clinical Epidemiology. 2013.
39. Prasad V, Jena AB. Prespecified falsification end points: Can they validate true observational associations? JAMA. 2013.
38. Prasad V, Ho N. In vitro versus in vivo culture sensitivities: An unchecked assumption? Southwest Journal of Pulmonary Critical Care. 2013.
37. Prasad V, Cifu A. The reversal of cardiology practices: interventions that were tried in vain. Cardiovascular Diagnosis and Therapy. 2013.
36. Prasad V. Why resident physicians stay late. Canadian Medical Association Journal. 2013.
35. Prasad V. Persistent reservations against the premedical and medical curriculum. Perspectives on Medical Education. 2013.
34. Prasad V. Taking care of sick patients. Canadian Medical Association Journal. 2013.
33. Prasad V. Why randomized controlled trials are needed to accept new practices: 2 medical worldviews. Mayo Clinic Proceedings. 2013.
32. Prasad V. The overdiagnosis of pneumonia. Cleveland Clinic Journal of Medicine. 2013.
31. Prasad V. Double-crossed: Why crossover in clinical trials may be distorting medical science. Journal of the National Comprehensive Cancer Network. 2013.
30. Kim JK, Rho J, Prasad V. Handheld ultrasounds: pocket sized, but pocket ready? American Journal of Medicine. 2013.
29. Kim J, Rho J, Prasad V: Evidence-based practice in chronic musculoskeletal pain? Alternative and Complementary Therapies. 2013
28. Jena AB, Prasad V. Duty hour reform in a shifting medical landscape. Journal of General Internal Medicine. 2013.
27. Ioannidis JP, Prasad V. Evaluating health system processes with randomized controlled trials. JAMA Internal Medicine. 2013.
26. Huded C, Rosno J, Prasad V. When research evidence is misleading. American Medical Association Journal of Ethics. 2013.
25. Ho N, Kim J, Prasad V. Dense breasts and legislating medicine. Cleveland Clinic Journal of Medicine. 2013.
2012
24. Prasad V, Cifu A. A medical burden of proof: Towards a new ethic. BioSocieties. 2012.
23. Prasad V, Vandross A. Cardiovascular primary prevention: How high should we set the bar? Archives Internal Medicine. 2012.
22. Prasad V, Rho J, Selvaraj S, Toomey C, Vandross A, Ho N. Publication trends among Internal Medicine residents and graduates. The American Journal of Medicine. 2012.
21. Prasad V, Rho J, Cifu A. The diagnosis and treatment of pulmonary embolism: A metaphor for medicine in the evidence-based medicine era. Archives Internal Medicine. 2012.
20. Prasad V, Kaplan RM, Passman RS. New frontiers for stroke prevention in atrial fibrillation. Cerebrovascular Disease. 2012.
19. Prasad V, Cifu A, Ioannidis JP. Reversals of established medical practices: Evidence to abandon ship. JAMA. 2012.
18. Prasad V, Cheung M, Cifu A. Chest pain in the emergency department: The case against our current practice of routine noninvasive testing. Archives of Internal Medicine. 2012.
17. Prasad V. An unmeasured harm of screening. Archives of Internal Medicine. 2012.
16. Prasad V. Holiday reading: The facts are the facts. Canadian Medical Association Journal. 2012.
15. Prasad V. The apples and oranges of cost-effectiveness. Cleveland Clinic Journal of Medicine. 2012.
2011
14. Straus D, Prasad V, Munoz L. Selective therapeutic hypothermia: a review of invasive and noninvasive techniques. Arquivos de Neuro-Psiquiatria. 2011.
13. Prasad V, Thistlethwaite W, Dale W. Effect of clinical vignettes on senior medical students' opinions of climate change. Southern Medical Journal. 2011.
12. Prasad V, Gall V, Cifu A. The frequency of medical reversal. Archives of Internal Medicine. 2011.
11. Prasad V, Cifu A. Medical reversal: Why we must raise the bar before adopting new technologies. The Yale Journal of Biology and Medicine. 2011.
10. Prasad V, Bonow RO. The cardiovascular biomarker conundrum: challenges and solutions. JAMA. 2011.
9. Prasad V. Why there must be a meditative medicine. Alternative and Complementary Therapies. 2011.
8. Prasad V. Are we treating professionalism professionally? Medical school behavior as predictors of future outcomes. Teaching and Learning in Medicine: An International Journal. 2011.
7. Ho N, Prasad V. Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation. Journal of Clinical Gastroenterology. 2011.
2010
6. Prasad V. Holiday reading: A la carte medicine. Canadian Medical Association Journal. 2010.
5. Prasad V. Reclaiming the morbidity and mortality conference: Between Codman and Kundera. Medical Humanities. 2010.
4. Prasad V: Language in the end. Explaining the death of a loved one. Journal of General Internal Medicine. 2010.
3. Prasad V. Beyond storytelling in medicine: An encounter-based curriculum. Academic Medicine: Journal of the Association of American Medical Colleges. 2010.
2. Prasad V. Baseline event rate, the concorde fallacy, and the topography of cardiac risk. Medical Hypotheses. 2010.
2009
1. Prasad V. Toward a Meaningful Alternative Medicine. The Hastings Center Report. 2009.